Proactive Investors - Run By Investors For Investors

Emerald Health Therapeutics receives Health Canada licenses for its natural products line

The products were designed to treat stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients
Spoons filled with vitamins
The Endo product line is expected to launch in mid-2019

Cannabis company Emerald Health Therapeutics Inc’s (CVE:EMH) (OTCQX:EMHTF) joint venture, Emerald Health Naturals has received products licenses and natural products numbers from Health Canada for its Endo product line.

The line of nutritional products was developed by Emerald Health Bioceuticals Inc alongside its scientific advisors.

READ: Level Brands shares soar after deal to buy CBD brand cbdMD

The products, including Endo Sleep, Endo Inflame, Endo Brain, Endo Bliss and Endo Calm, were designed to treat stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

“We have the unique opportunity to brand Emerald through EHN’s offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” said Executive Chairman Avtar Dhillon.

The line is expected to launch in mid-2019 and will be available in natural health stores, grocery stores and pharmacies.

Dhillon said that Emerald will be well-positioned to add cannabinoid compounds to Endo products if CBD and other non-psychoactive cannabinoid products are allowed to be sold via these channels going forward.

While recreational marijuana has been legalized in Canada, the legality of CBD is still in question.

Shares of Emerald Health were down about 6% to US$2.02 in Tuesday Morning trading.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full EMH profile View Profile

Emerald Health Therapeutics Inc Timeline

Related Articles

immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use